MindBio Therapeutics Past Earnings Performance
Past criteria checks 0/6
MindBio Therapeutics has been growing earnings at an average annual rate of 93.6%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually.
Key information
93.6%
Earnings growth rate
93.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How MindBio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | 0 | 1 | 0 |
| 30 Jun 24 | 0 | 0 | 1 | 0 |
| 31 Mar 24 | 1 | -4 | 3 | 0 |
| 31 Dec 23 | 0 | -4 | 3 | 0 |
| 30 Sep 23 | 0 | -4 | 3 | 0 |
| 30 Jun 23 | 0 | -4 | 3 | 0 |
Quality Earnings: WF6 is currently unprofitable.
Growing Profit Margin: WF6 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if WF6's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare WF6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WF6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: WF6's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.